Trial Profile

RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larsucosterol (Primary) ; Methylprednisolone
Indications Alcoholic hepatitis
Focus Registrational; Therapeutic Use
Acronyms RE-AHFIRM
Sponsors Bausch Health Companies; DURECT Corporation

Most Recent Events

25 Feb 2026 Status changed from planning to recruiting.
11 Sep 2025 According to a Bausch Health media release, DURECT Corporation has been acquired and merged into Bausch Health Companies.
26 Mar 2025 According to a DURECT Corporation media release, topline results expected within two years of trial initiation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com